The choice of АСЕ inhibitor concerning renal protection

1. Mac Mahon N.B., Cauman S. Effects of ACE inhibitors, calcium antagonists, and other blob pressure towering drugs: results of prospectively designed overviews of randomized trials. BPLTCT, Lancet 2004: 345: 1076-8.

2. Koch M., Thomas B., Tschope E. et al. Survival and predictors of death in dialyzed diabetic patients. Diabetologia 1993; 10: 1515-6.

3. Walker W.G., Cutler J. et al. Blood pressure and renal junction in the Multiple Factor Intervention Trial (MRFIT). J Hypertens 1990; 8 (Suppl. 3): VA. 3.

4. Kafettz K. Renal impairment in the elderly: a review. J R Soc Med 1983; 76: 398-401.

5. Hasslacher C., Ritz E., Wahl P. et al. Similar risks of nephropathy in patients with type I and type I diabetes mellitus. Nephrol Dialysis Transpl 1994; 9; 1097-102.

6. Biesenbach G., Janco O., Zazgornic J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus Nephrol Dialysis Transpl 1993; 36: 1071-8.

7. Deedwania P.C. Hypertension and diabetes: new therapeutic options. Arch Intern Med 2000: 160: 1985.

8. Freidman J.R., Norman D.S., Yoshikawa T.T. et al. Correlation of estimates renal function parameters i visits 24-hour creatinine clearance in ambulatory elderly. J Am Geriatr Soc 1989; 37: 145-9.

9. Rostand S.G., Brown G., Kirk K.A. et al. Renal insufficiency in treated hypertensive patients. N Engl J Med 1989; 320: 684-8.

10. Hall A.S. Ace inhibition and target organ protection 1998; Hoechst Marion Roussel. Chapter 7.

11. Lewis E.J., Hunsicker L.G., Bain R.P. et al. The effect of ACE inhibition on diabetic nephropathy: N Engl Med 1993: 329: 1456-62.

12. Viherti G.C., Mogenson C.E., Groop L.C. et al. Effects of captopril on progression of clinical proteinuria in patients with insulin-dependent diabetes mellitus. JAMA 1994; 271: 275-9.

13. Laffel L.M.B., McGill B., Gans D.G. et al. The beneficial effect of ACE with captopril on diabetic nephropathy in patients with type I diabetes mellitus. Am J 1995: 99: 497-504.

14. Ravid M., Lang R., Rachmani R. et al. Long-term renoprotective effect of ACE inhibition in non-insulin-dependent diabetes mellitus. Arch Intent Med 1996, 156: 286-9.

15. Trevisan R., Tiergo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mils hypertensive non-insulin diabetic patients Am J Hypertension 1995: 8: 876-83.

16. Lebovitz H.E., Weigrmann T.B., Cnaan A. et al. Renal protect ice effects of enalapril in hypertensive N1SSM: role of baseline albuminuria. Kidney Int 45: S150-S155.

17. Penegrer T.V., Klag M.J, Feldman H.I. et al. Projections of hypertension-related renal disease in middle-aged residents of the United States. JAMA 1993: 269: 1272-7.

18. Ruilope L.M., Alcazar J.M., Hernandez E. et al. Long-term influence of antihypertensive therapy on microalbuminuria in essential hypertension Kydney Int 1994: 45: 171-3.

19. Martinez M., Moreno A., Aguirre A. et al. Frequency and determinants of microalbuminuria in mild hypertension: a primary-care-based study. J Hypertension 2001; 19: 319-26.

20. Debusmann E.R., Pujadas J.O., Lahn W. et al. Influence of renal junction on the pharmacokinetics of ramipril. Am J Cardiol 1987: 59: 70D-78D.

21. White C.M., Pharmacologic, pharmakinetic and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998: 18: 588-98.

22. Veller W. Treatment of Senile hypertension. The fosinopril in old patients study. AJH 1997: 10: 255S-261S.

23. Diercks G.F., Janssen W.M., van Boven A.J. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive. nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]. Am J Cardiol 2000 Sep 15: 86 (6): 635-8.

24. Costanzi S., Fulignati P., Passalacqua S. et al. Nephritic syndrome and ACE inhibitors. Nephrol Dial Transplant 1992: 706-7.

25. Rodicio J.L., Praga M., Alcazar J.M. Effetcs of ACE inhibitors on the progression of renal failure and proteinuria in humans. J Hypertens 1989; 7: 543-9.

26. Cansevoort R.T., Sluiter W.L., Hemmelder M.G. et al. Antiproteinuretic effect of blood pressure lowering agents: a metaanalysis of clinical trials. Nephrol Dial Transplant 1995: 10: 1963-74.

27. Ruiple M.R., Aranda A.P., Diez S.J. et al. A random comparison of fosinopril and nifedipine GIIS in patients with primary renal disease. J Hypertens 2001: 10: 1871-6.

28. Wei A., Burns G.C., Williams B.A. et al. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int 2003: 64: 1462-71.

29. Zannad F., Kessler M., Grundfeld J.P., Thuilliez C. FOSlnopril in DIALysis Investigators. F0SIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics. Fundam Clin Pharmacol 2002; 16: 353-60.

30. Greenbaum R., Zucchelli P., Caspi A. et al. Comparison of the pharmacokinetics off fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Br J Clin Pharmacol 2000 Jan: 49 (1): 23-31.

31. Goldszer R., Iruine G. Renal find ion on prolonges obesity. Kydney Int 1989; 25: 165-9.

32. Stockholm K.H., Increased glomerular filtration rate and adrenocortical function in obese women. Int J Obes 1980; 4: 57-63.

33. Praga M., Hernandex E., Andres et al. Effects of body weight loss and captopril treatment of proteinuria associated with obesity. Nephrol 1995; 70: 35-41.

34. Fogari R., Zoppi P., Rinaldy A. et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetes patients. Am J Hypertens 2002; 15: 1042-9.

35. O'Grady P., Yee K.T., Linz R., Mangold B. Fosinopril hydrochlorothiazide: sinfle dose and steady-state pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 1999: 48: 375-81.

36. Huang Y.H., Wang H.T., Zhu Qz. et al. Combination therapy with losartan and fosinopril for elderly diabetic nephropathy. Di Yi Jun Da Xue Bao 2003; 23: 963-5.